J&J stays focused on early-stage deals; Ionis bags a milestone from GSK;

@FierceBiotech: Biden maps out a 'moonshot' approach to cancer with plans to 'break down silos' in R&D. More | Follow @FierceBiotech

@JohnCFierce: FDA slaps down BioMarin's Duchenne's drug as rival nears a moment of truth. News | Follow @JohnCFierce

@DamianFierce: "I made a point to talk to female guests," he said. More from Bloomberg | Follow @DamianFierce

> Bloomberg reports that J&J ($JNJ) chief Alex Gorsky plans to continue a strategy of acquiring early-stage treatments rather than switch to a megamerger approach. Story

> Ionis Pharmaceuticals, formerly Isis, has earned a $1.5 million milestone from GlaxoSmithKline after launching a Phase I study of the hep B drug IONIS-HBV-LRx. Release

Medical Device News

@FierceMedDev: Medical device sales reps scouting out new jobs in 2016: Report. More | Follow @FierceMedDev

@EmilyWFierce: Olympus, FDA implicated in Senate probe of duodenoscope devices. Report | Follow @EmilyWFierce

> Hospira pump business nears chopping block as Pfizer mulls potential sale: Bloomberg. More

> FDA makes increasing use of 'real-world' device data a strategic priority. Report

> JPM: Boston Sci updates on Watchman reimbursement, Synergy launch. Article

Pharma News

@FiercePharma: U.S.-based Certara creates drug developing consultancy in China. FiercePharmaAsia story | Follow @FiercePharma

@EricPFierce: J&J will boost workforce at South Africa consumer meds plant after $18M upgrade. More from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce:   head Slaoui says the company's vax and  businesses need each other--aka, no break-up, please. Article | Follow @CarlyHFierce

> For its next pare-down move, Pfizer weighs sale of Hospira pump business: Bloomberg. More

> FTC stats show pharma backing off pay-for-delay deals after SCOTUS ruling. Report

> Pfizer expands consumer biz in China with Treerly supplements buy. Article

Pharma Manufacturing News

> U.K.'s Oxford BioMedica gets MHRA nod for new manufacturing facility. Item

> GSK turns to K+N for supplier logistics. News

> FDA finds issues with Walgreens' infusion compounding services. Report

> EMA says Spain has taken action against drugmaker for shortcomings. Story

> Bayer opens large China plant for traditional Chinese and Western OTC meds. Article

CRO News

> Evotec hits an R&D milestone with J&J in an ambitious Alzheimer's collaboration. News

> Eurofins buys Dutch drug-testing firm to pad its services. More

> AMRI signs a trio of deals in R&D, manufacturing and marketing. Report

> Catalent inks a $619M deal to help Roche develop targeted therapies. Article

Pharma Asia News

> China-focused CASI Pharmaceuticals gets Marqbio review by CFDA. Item

> China continues to find problems in drug production. Article

> In Japan, fast approvals, more R&D cash and price cuts ahead. Report

> Astellas, Medivation report successful enzalutamide mCRPC PhII data in Lancet. More

> Cipla says top 50 drugs in development could bring in $30B. Story

Suggested Articles

The inclusion of Kupffer cells in in vitro hepatic cultures provides researchers with advanced tools for disease modeling and drug discovery.

A delay to Moderna's phase 3 COVID-19 study is part of a trend of tensions in the biotech’s relationship with the U.S. government, Reuters reported.

GlaxoSmithKline is continuing its strategy of giving out access to its vaccine platform as it adds Medicago to its growing partners list.